Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 103,360

Document Document Title
WO/2014/117680A3
The invention discloses the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Furthermore, the present invention sets forth the use of a classic transient receptor potential channel ...  
WO/2014/117700A1
The present invention provides a protopanoxadiol derivative of structural formula I or II, a preparation method and an application thereof. The present invention performs structural modification on protopanoxadiol, and obtains multiple n...  
WO/2014/119649A1
 The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having...  
WO/2014/117919A1
The present invention relates to novel substituted pyridine derivatives as positive allosteric modulators for modulating metabotropic giutamate receptor subtype 3 (mGluR3) and/or altering giutamate level or glutamatergic signalling.  
WO/2014/117669A1
Disclosed is a benzisoselenazolone-containing donepezil analog as represented by formula I and in either the form of a free radical, the form of a salt or the form of a solvate, also disclosed are a pharmaceutical composition comprising ...  
WO/2014/118133A1
The present invention relates to new kinase inhibitors of Formula (I) or a stereoisomer, tautomer, racemic, salt, hydrate, or solvate thereof, and more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, compris...  
WO/2014/117670A1
The present application provides a styryl quinoline compound represented by formula I and the use thereof in a pharmaceutical composition for treating, improving, and/or preventing Alzheimer's disease. R1-R7 are as defined in the descrip...  
WO/2014/120658A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I,...  
WO/2014/118307A1
The present invention relates to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidcne)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal form...  
WO/2014/120994A1
The present invention provides compounds of formula I or a salt, solvate, or stereoisomer thereof, wherein X is H, or an electron withdrawing group such as a halogen, NH2, NO2, SO2, CN, or a C1-C6 alkyl group; Alk is C1-C3 alkyl; R1 is H...  
WO/2014/117680A2
The invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Specifically, the present invention provides a classic transient receptor potential channel 6 (TPRC6) g...  
WO/2014/117863A1
The present invention relates to novel crystal forms of 4-(6-ethoxy-l-methoxy-thioxanthene-9- ylidene)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal for...  
WO/2014/120654A1
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2014/120815A1
The invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: formula (I). The invention also provides pharmaceutically acceptable compositions comprising the com...  
WO/2014/117220A1
The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.  
WO/2014/120538A1
Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT131.  
WO/2014/116015A3
The present invention provides a functional composition for preventing Alzheimer's disease, containing a heat-treatment salt heat treated at 800-1,200℃ as an active ingredient, and other pharmaceutically or cytologically acceptable ing...  
WO/2014/115885A1
 The present invention provides a novel therapeutic agent for demyelinating disease which acts to suppress the demyelination of the neuroaxis. The present invention provides a therapeutic agent for demyelinating disease, the therapeuti...  
WO/2014/117089A1
A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with los...  
WO/2014/116652A2  
WO/2014/116015A2
The present invention provides a functional composition for preventing Alzheimer's disease, containing a heat-treatment salt heat treated at 800-1,200℃ as an active ingredient, and other pharmaceutically or cytologically acceptable ing...  
WO/2014/116666A1
The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder. In general, the individuals are treated and/or classified based on the presenc...  
WO/2014/115072A1
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.  
WO/2014/114248A1
The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of disea...  
WO/2014/114532A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2014/116132A1
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the cre...  
WO/2014/114186A1
The present invention belongs to the field of pharmaceutical techniques, and in particular relates to JNK inhibitors as shown by general formulae (I), (1a) or (1b), pharmaceutically acceptable salts or stereoisomers thereof, the preparat...  
WO/2014/114694A1
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for e...  
WO/2014/114742A1
A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2...  
WO/2014/116739A1
Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.  
WO/2014/113878A1
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...  
WO/2014/115853A1
The propellane derivatives represented by general formula (I) or pharmaceutically-acceptable acid addition salts thereof, or hydrates or solvates of said propellane derivatives and acid addition salts are used as analgesics, antidepressa...  
WO/2014/115098A1
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/117176A1
The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) β-alanine or a...  
WO/2014/114779A1
The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, moto...  
WO/2014/115430A1
The present invention provides: a humanized anti-HMGB1 antibody that binds specifically to a sequence consisting of an eight-amino-acid residue (EEEDDDDE) at the C terminal of the HMGB1 protein, and that is effective in the treatment or ...  
WO/2014/113844A1
The present invention relates to the field of biomarkers and in particular to their utilisation in treatment. Embodiments of the invention have been particularly developed as biomarkers enabling optimisation of treatment regimes and as u...  
WO/2014/114032A1
A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the ...  
WO/2014/114627A1
The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a phannaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the b...  
WO/2014/114695A1
The present invention relates to novel pyrimidine derivatives of formula (I)[Formula should be entered here] as inhibitors of the enzyme phosphodiesterase 10 (PDE-10), pharmaceutical compositions comprising an effective amount of these c...  
WO/2014/113750A1
The invention comprises novel inhibitors of dipeptidyl peptidase IV (DPP-IV) with beta blocker activity, pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP-IV, and novel methods of treatin...  
WO/2014/111457A1
The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are ...  
WO/2014/112676A1
The present invention relates to a massage oil for deep sleep in which a valerian oil, a lavender oil, and a chamomile roman oil are mixed. According to the present invention, the massage oil effectively treats insomnia and especially sh...  
WO/2014/111751A1
The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/o...  
WO/2014/111957A1
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the prep...  
WO/2014/113609A1
Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indo...  
WO/2014/112152A1
Provided is a medicine used as an external preparation for treatment of local symptoms of neuropathic disease, wherein gabapentine or pregabalin is contained in the form of an aqueous solution.  
WO/2014/113539A1
The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as treatment for neuronal injury such as spinal cord injury. Botulinum neurotoxin binds to neural cells ...  
WO/2014/111028A1
Disclosed in the present invention are a new genistein alkylamine compound (I) and pharmaceutically acceptable salts thereof, and the preparation method and use thereof in the preparation of drugs for the treatment and/or prevention of d...  
WO/2014/111496A1
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, ...  

Matches 351 - 400 out of 103,360